ArticleRSC pharmaceutics2026
Systematic development and optimization of a microfluidic formulation protocol for liposomal azithromycin.
Abdullah A Masud, Nabilah Ibnat, Areli Medina Hernandez, Kaysi M Lee, Sophia Li, Ryan Marion, David J Feola, Vincent J Venditto
Abstract read
In one paragraphArticle in RSC pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Abdullah A MasudDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington KY 40536 USA Vincent.venditto@uky.edu.
Nabilah IbnatDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington KY 40536 USA Vincent.venditto@uky.edu.
Areli Medina HernandezDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington KY 40536 USA Vincent.venditto@uky.edu.
Kaysi M LeeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington KY 40536 USA Vincent.venditto@uky.edu.
Sophia LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington KY 40536 USA Vincent.venditto@uky.edu.
Ryan MarionDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington KY 40536 USA Vincent.venditto@uky.edu.
David J FeolaDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky Lexington KY 40536 USA.
Funding
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jon Scott Thorson · 2020 to 2026
$18.7MKentucky Network for Innovation & Commercialization (“KYNETIC”)U01HL152392 · NHLBI · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P, MERTEN, KEVYN E · 2019 to 2022
$3.9MMacrophage Depletion Therapy for Spinal Cord InjuryR01NS116068 · NINDS · UNIVERSITY OF KENTUCKY · PI ALILAIN, WARREN JOSEPH, GENSEL, JOHN C · 2021 to 2025
$3.0MThe role of macrophage phenotype and age in spinal cord injuryR01NS091582 · NINDS · UNIVERSITY OF KENTUCKY · PI GENSEL, JOHN C · 2015 to 2019
$1.6MUnderstanding the role of immune complexes between apolipoprotein A-I and IgG in atherosclerotic cardiovascular diseaseR01HL152081 · NHLBI · UNIVERSITY OF KENTUCKY · PI VENDITTO, VINCENT JOSEPH · 2020 to 2023
$1.5MLiposomal azithromycin to treat cardiac inflammationR61HL177474 · NHLBI · UNIVERSITY OF KENTUCKY · PI Ahmed Abdel Latif, David Feola · 2025 to 2026
$1.1MNHLBI NIH HHS R01 HL152081NHLBI NIH HHS R61 HL177474NHLBI NIH HHS U01 HL152392NIGMS NIH HHS P20 GM130456NINDS NIH HHS R01 NS091582NINDS NIH HHS R01 NS116068
6 · The paper itselfAbstract
Identifiers
PMID41280506
PMCPMC12633639
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390